A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-22

Study Completion Date

2009-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare by neuroimaging techniques the way Social Anxiety patients respond to public speaking before and after a drug administration

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients

NCT00343707

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE2

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

NCT00273039

Social Anxiety Disorder Anxiety Disorders

COMPLETED PHASE2

A Combination Therapy In Patients With Social Anxiety Disorder

NCT00403962

Social Phobia

COMPLETED PHASE2

A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

NCT00555139

Social Phobia

COMPLETED PHASE1

Social Anxiety Disorder Study Of Paroxetine

NCT00318669

Social Phobia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Phobia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

arm 1

Paroxetine treatment during 8 weeks

Group Type ACTIVE_COMPARATOR

Paroxetine treatment during 8 weeks

Intervention Type DRUG

treatment drug

arm 2

Placebo treatment during 8 weeks

Group Type PLACEBO_COMPARATOR

Placebo treatment during 8 weeks

Intervention Type DRUG

comparator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo treatment during 8 weeks

comparator

Intervention Type DRUG

Paroxetine treatment during 8 weeks

treatment drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo treatment during 8 weeks

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatient with Social Anxiety Disorder
* The subject is healthy
* Willing to restrict alcohol intake
* Capable of giving informed consent

Exclusion Criteria

* Subjects with depression or any other psychiatric condition
* Subjects positive for HIV or hepatitis
* Subjects taking drugs or other medication
* Pregnant or becoming pregnant during the study
* Subjects who have donated blood
* Subjects who are left-handed
* Subjects with claustrophobia
* Subjects with an electronic device or ferromagnetic metal foreign body

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.